Oppenheimer Turns Bullish on Savara as Molgramostim Moves Closer to Approval
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
/ 2 items
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.